ABBISKO-B(02256): The FGFR4 inhibitor erdafitinib has completed the global phase I study extension stage with the first patient dosed in the United States.

08:03 11/02/2026

Honor-B (02256) announced that its subsidiary, Shanghai Hoyu Biomedical Technology Co., Ltd. (Hoyu Biomedical), has successfully administered the first patient in a global multicenter phase I clinical trial (ABSK-011-101) of its independently developed highly selective small molecule FGFR4 inhibitor, Irpagratinib (ABSK-011), targeting FGF19-overexpressing advanced hepatocellular carcinoma (HCC) in the United States. Previously, Irpagratinib has been granted Fast Track Designation (FTD) by the Food and Drug Administration (FDA) in the United States, which is expected to further accelerate its global clinical development process.

ABBISKO-B(02256) announcement: ABBISKO's subsidiary Shanghai Heyu Biomedical Technology Co., Ltd. (Heyu Medicine) announced that its independently developed highly selective small molecule FGFR4 inhibitor Irpagratinib/ABSK-011 has successfully completed the first patient dosing in a global multicenter Phase I clinical study (ABSK-011-101) targeting advanced hepatocellular carcinoma (HCC) with FGF19 overexpression in the United States. Previously, Irpagratinib has been granted Fast Track Designation (FTD) by the Food and Drug Administration (FDA) in the United States, which is expected to further accelerate its global clinical development process.

Valuation doubled to 350 billion in half a year! Blackstone (BX.US) invested an additional 200 million, increasing its total stake in Anthropic to 1 billion dollars.

HK Stock Market Move | TVB (00511) rose by over 11%, expected to turn losses into profits last year and earn over 50 million Hong Kong dollars.

HK Stock Market Move | WUXI BIO (02269) opened over 3% higher in the morning, with an expected net profit of 4.908 billion yuan in 2025, a year-on-year growth of 46.3%.

Valuation doubled to 350 billion in half a year! Blackstone (BX.US) invested an additional 200 million, increasing its total stake in Anthropic to 1 billion dollars.

HK Stock Market Move | TVB (00511) rose by over 11%, expected to turn losses into profits last year and earn over 50 million Hong Kong dollars.

HK Stock Market Move | WUXI BIO (02269) opened over 3% higher in the morning, with an expected net profit of 4.908 billion yuan in 2025, a year-on-year growth of 46.3%.